Hermann Bujard (1934-2020) - pioneering researcher and visionary science politician by Bukau, B. et al.
Obituary
Hermann Bujard (1934–2020) –
pioneering researcher and visionary
science politician
Bernd Bukau1, Michael Lanzer2, Fritz Melchers3 & Gerlind Wallon4,*
On July 31, 2020, Hermann Bujard
(*16.04.1934) passed away. Hermann
pioneered our understanding of gene
promoters, developed the widely used Tet
system to induce and precisely tune gene
expression, and advanced the development
of a malaria vaccine from basic research to
phase I clinical trials. He was also an excep-
tional person who touched many people’s
lives as a teacher and mentor, an advocate
for liberal research structures similar to
those he implemented at the Center for
Molecular Biology of Heidelberg University
(ZMBH), and a visionary science politician.
Hermann was born in 1936 in Heidelberg,
Germany, and grew up in Freiburg as one of
five children of a protestant priest. He often
said that the high moral values taught and
lived by his father had imprinted him for
life. After his PhD in organic chemistry in
Göttingen, Hermann left for the United
States in 1962, inspired by the tea hours held
by Manfred Eigen, to do his postdoc with
Charly Heidelberger and Gobind Khorana in
Madison, Wisconsin. After only 2 years, he
was offered an assistant professorship at the
Southwest Center for Advanced Studies in
Dallas, Texas, where he started his research
on DNA structure and DNA–protein interac-
tions. When he was appointed as a professor
of molecular genetics at Heidelberg Univer-
sity in 1970, he, his wife, and two children
moved to Heidelberg where he changed his
focus to study transcriptional control mecha-
nisms in prokaryotes. Hermann teamed up
with a colleague, Peter von Sengbusch, to
work out a new curriculum, which trans-
formed teaching at the faculty. Well-trained
students with a strong background in molec-
ular biology soon became a treasure of the
faculty.
In the early 1970s, EMBO invited propos-
als for a laboratory to be set up somewhere
in the Federal Republic of Germany. Munich
initially seemed the most likely choice, but
Hermann, Peter, and Ken Holmes, during
long nights, worked out a compelling
proposal, so that Heidelberg eventually got
the nod for the EMBO/EMBL campus. The
proposal offered EMBO young talented local
students taught by the modernized biology
curriculum, and scientific cooperation with
local university departments, as well as the
Max Planck Institute for Medical Research
and the German Cancer Research Center
(DKFZ). The EMBO site committee arrived
in Heidelberg after having been wined and
dined in Munich, and Hermann and his
fellow campaigners, including the mayor of
Heidelberg and the directors of the different
institutes, took them to rather more down-
to-earth boisterous student pubs. The enthu-
siasm of the locals and the unique status
that the EMBO Lab would have in Heidel-
berg apparently convinced the committee.
This success also shows a characteristic of
Hermann that runs like a red thread
throughout his life: He was never shy to take
on a challenge and had the intelligence,
political wit, and tenacity to pull it through.
One of us (Fritz Melchers), at the time
the director of the Roche-owned Basel Insti-
tute for Immunology (BII), proposed to
Roche’s president to hire Hermann as the
director of a newly established section of
Molecular Biology. Hermann, having grown
unhappy with the conservative environment
at the University of Heidelberg at that time,
accepted and set up biomolecular research
at Roche. His influence on the future devel-
opment of the company cannot be overesti-
mated: He established the use of large
molecular weight pharmaceuticals, based on
his expertise on gene expression, which has
transformed Roche into what is today one of
the largest pharmaceutical companies.
After 3 years at Roche, he was hired back
to Heidelberg in 1986 to direct the newly
established ZMBH. Many visits to the ministry
in Stuttgart were necessary to give it the
constitution and departmental structure that
he desired, drawing on his experience of the
departments that he had seen in the United
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States. He wanted early independence for
young scientists, and an institute structure
that offers scientists maximal freedom to
pursue challenging research questions. Under
his 10-year directorship, the ZMBH developed
into an internationally highly recognized
research center that promoted countless
successful research careers.
Hermann had brought with him from
Roche a new project: the quest for a malaria
vaccine. He set up collaborations with Yeya
Touré and Ogoabara Doumbo in Mali and
went several times to Africa to collect serum
samples in endemic areas, once contracting
malaria himself. He often talked about the
children who were most at risk and that
many of them would no longer be alive
when they returned a year later to collect
more samples. He identified the major
surface protein 1 (MSP1) as the, in his well-
argued but challenged view, most promising
candidate for a protective antigen.
At that time, his group worked on a
tetracycline repressor-based gene switch,
the Tet system, together with his PhD
student and later postdoc Manfred Gossen.
Heidelberg University felt that the challenge
and effort to patent this were too large, so
Hermann set off to do this himself. His
company TET Systems was able to market
and innovate the technology such that it is
still today, some 25 years after the initial
discovery, making good profits from
licensing, which Hermann used to finance
the development of the malaria vaccine.
This was very much needed, since Hermann
had to realize that while the German
government was happy to fund his basic
research on malaria with millions of Euros,
there was no money available when it came
to translate his findings into an experimen-
tal vaccine.
In 2007, at the age of 73 and well into
his retirement, Hermann was asked to take
on the directorship of EMBO for a short
interim period until a new director was
found. His directorship turned into 3 years
during which he launched The EMBO Meet-
ing and changed the management structure
of EMBO Press among many other reforms.
Crucially, yet unnoticed by many, he saw to
it that the status of EMBO as a not-for-profit
organization registered in Switzerland, but
located in Heidelberg, was rendered legally
sound.
After his short but decisive stint at
EMBO, he returned to concentrate on the
malaria vaccine. In order to continue the
clinical evaluation of MSP1, Hermann
founded Sumaya Biotech in 2014. However,
since it was difficult to find capital, he even-
tually financed the manufacturing of full-
length MSP1 under GMP conditions and the
first-in-human study mostly out of his own
pocket. Sumaya Biotech will continue to
evaluate MSP1 in clinical trials and test the
prime/boost strategy in challenge studies in
Africa.
Hermann’s impact on German parasitol-
ogy cannot be overestimated. He was instru-
mental in revitalizing this discipline in
Germany and contributed to a road map
commissioned by the Deutsche Forschungs-
gemeinschaft (DFG). Hermann further
helped shaping the Zentrum für Infektions-
forschung at the University of Würzburg,
where he served as chair of the scientific
advisory board.
Over the course of his long life, Hermann
has received numerous prizes and awards
for his scientific oeuvre, such as the Beck-
urts Award, the Prix Yvette Mayent, the
Robert-Koch Gold Medal, and the Medal of
Merit of the Federal State of Baden-Wuert-
temberg. But he was most proud of the
feedback from his former students who
praised him as a great teacher and mentor.
With his sharp mind and impressive knowl-
edge in broad aspects of life, he was an
inspiring and stimulating discussion part-
ner, not afraid of controversies. At the same
time, he had a fine sense of humor and was
a delightful and charming storyteller.
Hermann was a great scientist, a charis-
matic and disarmingly humorous colleague,
mentor, and friend.
Honoré de Balzac said that you live
twice: once in reality, the second time, in
memories. In OUR memories.
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